PARIS (Reuters) – France’s top health agency will say on Friday that recipients of AstraZeneca’s original COVID-19 vaccine, under 55, should get a second vaccine with the vaccine. Messenger-RNA New model, two data sources realize The plan was said on Thursday.
Reuters reported on Wednesday that Haute Autorite de la Sante (HAS), responsible for establishing a method for the use of a vaccine approved by the European Medicines Agency (EMA) in France, is considering this possibility.
HAS has now decided to go ahead with the plan, two sources said, two mRNA vaccines, one from Pfizer and Biotech and one from Moderna, approved for use in France.
Messenger RNA vaccines stimulate the human body to make proteins that mimic part of the virus, triggering the immune response, while viral vector vaccines such as AstraZeneca use the common cold virus to perform DNA instructions to do the same.
The spokeswoman had no comment.
Vaccination programs have become widespread in Europe and elsewhere in recent months as the majority of AstraZeneca recipients suffer from a highly abnormal blood clot, forcing some countries to suspend their use. Precaution
Most come back to using fire, although there are some age restrictions.
In France, HAS suggested on March 19 that only people 55 and older should receive the 500,000 AstraZeneca vaccine for the first time.
Although the numbers are small compared to the tens of millions of people vaccinated across the European Union, the decision to give different stimulants is important because this method has not been tested in End-stage human trials
Germany was the first in Europe to recommend that people under the age of 60 who received their first injection of AstraZeneca should receive another product for a second dose.
Some experts say that because all vaccines target the same exogenous virus ‘hinder’ proteins, they can complement each other. But there is no evidence that this approach will work as well.